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Gene by environment (GxE) interaction studies have investigated the influence of a
number of candidate genes and variants for major depressive disorder (MDD) on the
association between childhood trauma and MDD. Most of these studies are
hypothesis driven and investigateonly a limitednumber of SNPs in relevant pathways
using differing methodological approaches. Here (1) we identified 27 genes and 268
SNPs previously associated with MDD or with GxE interaction in MDD and (2)
analyzed their impact on GxE in MDD using a common approach in 3944 subjects of
European ancestry from the Psychiatric Genomics Consortium who had completed
the Childhood Trauma Questionnaire. (3) We subsequently used the genome-wide
SNP data for a genome-wide case-control GxE model and GxE case-only analyses
testing for an enrichment of associated SNPs. No genome-wide significant hits and
no consistency among the signals of the different analytic approaches could be
observed. This is the largest study for systematic GxE interaction analysis in MDD in
subjects of European ancestry to date. Most of the known candidate genes/variants
could not be supported. Thus, their impact on GxE interaction in MDD may be
questionable. Our results underscore the need for larger samples, more extensive
assessment of environmental exposures, and greater efforts to investigate new
methodological approaches in GxE models for MDD.
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1 | INTRODUCTION
Major depressive disorder (MDD) is known to be substantially
heritable but also has a huge number of well-established environmen-
tal and lifestyle factors that contribute to the disease risk (Cerdá,
Sagdeo, Johnson, & Galea, 2010). Although the proportion of variance
attributable to genome-wide SNPs (SNP heritability) for MDD has
been estimated to be about 21–32% (Lee et al., 2013; Lubke et al.,
2012), there are only a few genome-wide significant hits for MDD or
depressive symptoms that have been detected to date (CONVERGE
consortium, 2015; Hek et al., 2012; Hyde et al., 2016; Okbay et al.,
2016) and their biological impact on depression is largely unknown.
Many factors could explain the lack of success so far including limited
sample size, the high symptom heterogeneity for MDD as well as the
strong contribution of environmental and, lifestyle factors and life
events (Flint & Kendler, 2014), and it has been hypothesized that
genetic factors need the presence of environmental triggers to exhibit
an effect on the individual (Caspi et al., 2003; Dunn et al., 2015).
Early childhood trauma (CT) is the most frequently investigated
environmental factor, which shows a high impact on major depression
and many other psychiatric disorders (Mandelli, Petrelli, & Serretti,
2015). Previous studies have suggested interaction effects between
CT and individual variants from several genes including the highly
studied serotonin-transporter-linked polymorphic region (5-HTTLPR)
(Caspi et al., 2003; Karg, Burmeister, Shedden, & Sen, 2011; Van der
Auwera et al., 2014), but also for BDNF, TPH2, FKBP5, DRD2 and many
other genes from candidate pathways (Appel et al., 2011; Grabe et al.,
2012; Mandelli & Serretti, 2013). These candidate gene approaches in
gene-environment (GxE) interaction analyses select single variants in
specific genes belonging to plausible disease-related pathways.
Although this approach seems sensible, there are many challenges in
this work. Many factors impact on their interpretation, not least non-
significant results are less likely to be taken forward for publication
generating a reporting bias (Duncan & Keller, 2011). Comparisons
between studies are difficult because of the different environmental
exposures considered such as stressful life events, abuse and neglect
subtypes, social support or living in rural/urban areas, different
methods of assessment (questionnaires vs. interviews), and the
different quantification of exposures (binary, categorical or continu-
ous) (Dunn et al., 2011; Mandelli & Serretti, 2013). Likewise, the
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phenotype definition varies between a binary lifetime major depres-
sion variable to a dimensional score of current depression. Moreover,
there are no common guidelines regarding how to perform GxE
analyses in MDD (type of regression model (linear or logistic model),
mode of action (multiplicative or additive), or assumed genetic effect
(additive, allelic, dominant or recessive model)). Until now, only two
GxE interaction analyses for depressive symptoms have been
performed on a genome-wide level. One was published by Dunn
et al. (2016) in a sample of African American and Hispanic women. In
N = 7179 African American women one genome-wide significant hit
was found near CEP350, a centrosomal protein which has never been
associated with a psychiatric phenotype before. Another study in a
Japanese population (N = 320) reported the genome-wide hit
rs10510057 near RGS10 (Otowa et al., 2016), but given the small
sample size this result should be regarded with caution. Both studies
performed a linear regression GxE analysis assessing the p-value of the
interaction term with a dimensional depression score as the outcome,
and stressful life events during the past 12 months as the
environmental exposure. Whether these findings can be replicated
in a population of European ancestry, although the environmental
exposure is different, needs to be elucidated.
Here, we focus on the most important known risk exposure for
MDD, early CT, and combine all cohorts from the Psychiatric Genomics
Consortium (PGC) with available CT and MDD data to perform gene-
environment (GxE) interaction. At the outset, despite being the largest
European ancestry study to date, we recognized that our study was
likely under-powered to detect GxE effects on a genome-wide level, so
we sought to reduce the multiple testing burden by screening the
literature and identified genes and SNPs previously implicated inMDD
or GxE in MDD. Our aims were 1) to analyze candidate variants, 2) to
compare different methodological approaches, and 3) to analyze the
genome-wide summary statistics of the GxE analyses for an
enrichment of significant findings. We hypothesize that candidate
genes/SNPs for a GxE interaction in MDD that have been proposed in
the past should at least show a nominally significant association
(p < 0.05) in our analyses.
2 | MATERIALS AND METHODS
2.1 | Participants
The PGC collates genome-wide genotypic and phenotypic data for
MDD (Psychiatric Genomics Consortium Steering Committee, 2009).
Subjects were recruited from the PGC wave two for MDD, with
phenotypic and genetic data of 16823 MDD cases and 25632
controls from 24 different cohorts with individuals from European
ancestry. All cases were diagnosed according to DSM-IV lifetime
MDD using structured diagnostic instruments from direct interviews
by trained interviewers or clinician-administered DSM-IV checklists.
Controls were screened for absence of MDD. Nine of these cohorts
also provide phenotyping of exposure to environmental factors as
risk for psychiatric disorders including CT. Five cohorts used the
most widely applied Childhood Trauma Questionnaire (CTQ) that
distinguishes between different dimensions of childhood abuse and
neglect (Bernstein et al., 2003) (Table S1): Cognition and Function in
Mood Disorders Study (COFAMS) from Australia (Baune & Air,
2016), the Netherlands Study of Depression and Anxiety (NESDA)
(Penninx et al., 2008), Radiant-UK from the United Kingdom (Lewis
et al., 2010), and two independent samples from the Study of Health
in Pomerania (SHIP) from Germany (Völzke et al., 2011). Six cohorts
used study-specific versions of CT assessment that do not capture all
five dimensions of abuse and neglect from the CTQ or used different
types of questions (Table S1): Depression Gene Network (DGN) from
the USA (Mostafavi et al., 2014), the Genetics of Recurrent Early-
Onset Depression (GenRED) from the USA (Holmans et al., 2007),
two independent samples from the Queensland Institute of Medical
Research (QIMR) from Australia (Nelson et al., 2002; Wray et al.,
2012), the psychiatric arm of the population-based CoLaus study
(PsyCoLaus) from Switzerland (Preisig et al., 2009) and the Bonn/
Mannheim study from Germany (BOMA) (Cichon et al., 2011). To
reduce the heterogeneity in our samples, we only included the five
studies that measured CT with the same standardized instrument
(CTQ). In addition, COFAMS was excluded from the analysis due to
the low number (N = 56) of MDD cases with available CTQ data.
2.2 | Childhood trauma questionnaire
The CTQ assesses CT, defined as trauma before the age of 16 (CTQ,
Table S1) (Bernstein et al., 2003), which covers three sub-scales of
abuse, sexual abuse, physical abuse and emotional abuse, as well as
two sub-scales of neglect, emotional neglect, and physical neglect, all
covered by five questions (range 1–5). This results in a score per
domain ranging from 5 to 25, and an overall CTQ continuous score
ranging from 25 to 125. Per domain, cutoffs from the CTQ manual
(Bernstein et al., 2003) were applied to get a broad definition of CT
separating no trauma from mild, moderatel, or severe trauma. CT
was transformed to a dichotomous abuse variable separating
childhood abuse in any of the three domains (1 = Yes) from no
abuse in all domains (0 = No) to address the skewness of the CTQ
score.
2.3 | Genotyping, quality control, and imputation
The cohorts were genotyped following their local protocols, after
which quality control and imputation to the 1000 genomes reference
panel (Abecasis et al., 2010) was conducted through the standardized
PGCpipeline (see SchizophreniaWorking Group of the PGC, 2014) per
cohort (PGC MDD: wave two GWAS results, In preparation). For
details see supplemental material.
2.4 | Statistical analysis
We performed these analyses in three steps: 1) Power calculation and
selection of candidate SNPs/genes for GxE analyses, 2) Analysis of the
candidate variants and genes in GxE, and 3) Analysis of the genome-
wide GxE GWAS results.
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2.4.1 | Different methodological approaches
Ourmain analytic models assuming additive genetic effects include (i) a
standard GxE analysis with a multiplicative interaction term and a
dichotomous environmental exposure (abuse 0/1) and (ii) case-only
analyses, recommended by VanderWeele (Explanation in Causal
Inference, 2015; VanderWeele, Hernández-Díaz, & Hernán, 2010),
with the dichotomous abuse 0/1 variable as well as the continuous
CTQ score as outcome (for overview see Figure 1). Case-only analyses
have a higher statistical power to detect GxE effects (Gauderman,
Zhang, Morrison, & Lewinger, 2013) than case-control GxE models
with a multiplicative interaction term and circumvent the statistical
difficulties of the low robustness of interaction terms. But these
models require that no gene-environment (G∼ E) correlation is present
(VanderWeele, 2015; VanderWeele et al., 2010). For all case-only
models G∼ E correlation in MDD negative controls was analyzed. We
usedMDD negative controls because these constitute of roughly 85%
of the population and can thus be used as an approximation for the full
population.
(1) GxE case-control (CC) interaction analyses included a
multiplicative interaction term between the SNPs and abuse 0/1
assessing the p-value for the interaction term. Analyses were
controlled for sex, the first three genetic principal components as
well as all SNPxCov and ABUSExCov interaction terms as recom-
mended by Keller (2014).
logit(MDD)∼ SNP + ABUSE + SNPxABUSE + sex + PC1 + PC2 +
PC3 + SNPxSEX + SNPxPC1 + SNPxPC2 + SNPxPC3 + ABUSEx-
SEX + ABUSExPC1 + ABUSExPC2 + ABUSExPC3
(2) MDD case-only (CO) analyses with abuse 0/1 as dependent
variable assessed the SNP p-value:
logit(abuse)∼ SNP + sex + PC1 + PC2 + PC3 if MDD= 1
(3) MDD CO analyses with CTQ score as dependent variable
assessed the SNP p-value:
(4) CTQ∼ SNP + sex + PC1 + PC2 + PC3 if MDD= 1
These three approaches enable the comparisons between CC GxE
and COy analysis as well as between dichotomous and continuous
measurement of CT (abuse 0/1 vs. CTQ-score).
As a sensitivity analysis, the CO analyses were also performed
assuming a dominant and recessive SNP effect (see supplement). This
analysis was empirically driven by the fact that in many candidate
studies for GxE in MDD dominant or recessive effects were found
(Mandelli & Serretti, 2013).
2.4.2 | GWAS and meta-analyses
For each of the four cohorts (SHIP-0, SHIP-TREND, NESDA, Radiant-
UK) GWAS have been performed as described above. A logistic
regressionmodelwas used for a binary outcome and a linear regression
model for a continuous outcome using PLINK (Chang et al., 2015).
Quantile-quantile (QQ) and Manhattan (MH) plots were generated
using R (https://cran.r-project.org/). The finalmeta-analysis comprised
N = 3944 individuals (N = 1891 MDD cases and N = 2053 controls).
The results were combined using an inverse variance-weighted fixed
effects meta-analysis in METAL (Willer, Li, & Abecasis, 2010) with the
following QC parameters; MAF > 0.05, info score > 0.6, HWE > 0.001
and including only SNPpresent in at least three of the four cohorts. The
genomic inflation factor λ for each study was calculated, and genomic-
control (GC) correction was applied when λ > 1. The I2 statistic was
used to evaluate between-study heterogeneity.
3 | RESULTS
The number of MDD cases and controls with and without CT are
summarized in Table 1. In each of the four cohorts the CTQ total score
as well as the abuse 0/1 variable were highly associated with MDD,
adjusted for sex and age.
3.1 | Power calculation and selection of candidate
genes/SNPs
The software Quanto (vs. 1.2.4) was used to determine the interaction
effect size we would be able to detect as genome-wide significant
given our sample (see Table S2). In the case-control GxE model with
N ≈ 1900 MDD cases, we would only be able to detect large effects
(OR ≥ 2.5) with a power of 80% for SNPswith highMAF (MAF ≥ 0.2). In
the case-only model with N ≈ 2000 MDD cases, we would be able to
detect large effects (OR ≥ 2.4) for SNPs with low MAF (5%), and
medium effects (OR > 1.5) with SNPswith largeMAF (50%). Because in
GWAS small effects (OR < 1.5) are observed, we assumed that with our
current sample size we were underpowered to detect genome-wide
interaction signals. Thus, we will focus on candidate SNPs and genes
for GxE in MDD.
Since the literature on candidate genes for MDD and GxE
interaction in MDD is very broad, we focused on papers that reviewed
the previous work in the field. The candidate list comprises SNPs/
genes that were taken from two major reviews (Mandelli & Serretti,
2013 forGxE interaction inMDD; Luo et al., 2016 for candidate genes/
SNPs in MDD). These candidates cover genes from central monoam-
inergic systems such as serotonin, dopamine or noradrenalin, from the
FIGURE 1 Overview of the seven different models and
approaches for GxE. [Color figure can be viewed at
wileyonlinelibrary.com]
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glutamatergic system, corticotrophin system, neurotropic system or
from inflammatory processes (e.g., SLC6A4, DRD2, COMT, NR1,
CRHR1, BDNF, FKBP5, NR3C1). We also included SNPs from recent
GWAS results for MDD or GxE interaction (Dunn et al., 2016; Hyde
et al., 2016; Otowa et al., 2016). The final list included 268 different
candidate SNPs (supplemental Table S4) and 27 candidate genes
(supplemental Table S6). From the candidate SNP list, 184 SNPs were
available in the meta-analyses after QC (most of these candidate SNPs
were excluded based on MAF < 0.05).
3.2 | Analysis of candidate SNPs/genes
The candidate genes/variants were analyzed using different method-
ological approaches. In the CO analyses the candidate SNPs revealed
no excess of G∼ E correlation (supplemental material, Table S7),
justifying continuation into case-only analyses. A full list of the results
from the candidate SNPs in all models is provided in supplemental
Table S4.
3.2.1 | Case-control GxE analysis with a multiplicative
interaction term
In the fully adjusted GxE model no candidate SNP reached statistical
significance after correcting for multiple testing (pcorrected set to 0.05/
184 ≈ 0.0003) and five SNPs showed nominal significance (p < 0.05),
which was fewer than expected by chance (expected N = 9):
rs2433320 (PDLIM5), rs1656369 (RSRC1), rs1539243 (IKBKE),
rs900144 (ARNTL), and rs6582078 (TPH2).
3.2.2 | Case-only approach on abuse 0/1 and CTQ
score
Abuse 0/1: From the candidate list, eight SNPs were at least nominally
significant in the additive SNP model: rs1656369 (RSRC1),
rs41423247/rs6191/rs33388 (NR3C1), rs1801262 (NEUROD1),
rs4763327 (EMP1), rs2433320 (PDLIM5). CTQ-score: Seven SNPs
from the candidate list were nominally significant in the additive SNP
model: rs909486 (CSF2RB), rs3754674 (NPAS2), rs9450282 (NT5E),
rs4244813/rs2279861 (SLC29A2), rs6191 (NR3C1), rs737865
(COMT). Results for the dominant/recessive case-only models can
be found in supplementary Table S4.
3.2.3 | Exploratory comparison of all three
approaches
Taking the CC GxE and CO GxE approaches, only 16 (≈9%) of the 184
SNPs showed nominal significance in at least one of the approaches
(Table S4), 13 of them with consistent directions of effects in all three
approaches. Some of them showed consistently significant associa-
tions across approaches. Two SNPs (rs33388 and rs6191) of NR3C1
(glucocorticoid receptor) which acts as a transcription factor and player
in the hypothalamic-pituitary-adrenal (HPA) axis could be supported
(Keller et al., 2016) in both case-only models but not in the direct GxE
interaction. Rs2433320 in PDLIM5 (PDZ and LIM domain containing 5)
and rs16566369 in RSRC1 (arginine and serine rich coiled-coil 1)
showednominal significant results in at least two different approaches.
3.3 | GWAS to identify GxE interaction loci
Meta-analysis of all four cohorts included nearly 4.3 million
variants. An overview of the top loci in all three models, assuming
an additive SNP-effect, is given in Table 2. In all three meta-
analysis no SNP achieved genome-wide significance (all p > 5E-8).
The top SNPs from the genome-wide CO approaches revealed no
excess of gene-environment correlation (supplemental material,
Table S7).
Manhattan-plots for all three models are given in supplemental
Figure S1. The quantile-quantile plots showed a deflation of the
observed results to those expected by chance (supplemental Figure S2)
and the λs were between 0.96 and 0.99. A full list of SNPs with p < 1E-
5 in all different approaches is given in supplemental Table S3.
The top-hit in the case-control GxE approach on abuse 0/1 assuming
an additive SNP effect was the variant rs7128637 near the ARHGAP20
gene, a Rho GTPase activating protein, with p= 4.4E-6. The top hit in the
case-only analysisonabuse0/1was rs17578476 (p = 3.3E-6) harboringat
LRRIQ3 Locus, a locus previously implicated as one of the 108 Loci
associated with schizophrenia (Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014). In the case-only analysis for
CTQscore theminimum p-valuewas achieved for rs3214187 (p = 7.4E-7)
near theNPY (neuropeptideY)gene.Another topvariant fromthis analysis
was rs75184661 (p =4.1E-6), intronic of CACNA1C (subunit of calcium
voltage-gated channel). Results for the dominant/recessive case-only
models can be found in supplementary Table S3.
TABLE 1 Sample description and descriptive statistic of the four samples included in the meta-analysis
MDD cases Controls MDD ∼ abuse
N No abuse Abuse No abuse Abuse Odds ratio p-value Abuse prevalence (%)
SHIP-0 1505 239 117 921 171 2.55 7.6E-11 19
SHIP-TREND-0 665 114 46 428 59 3.06 1.5E-6 16
NESDA/NTR 1396 500 627 208 61 4.19 1.1E-19 49
Radiant UK 525 85 175 199 66 6.09 2.6E-20 46
Total 4091 938 965 1756 357 – – –
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3.3.1 | Exploratory comparison of all three
approaches
The correlation between effect estimates (betas and log(OR)) of all
three genome-wide approaches assuming an additive SNP effect was
highest between both CO approaches on abuse 0/1 and CTQ-score
(r = 0.58), medium between both analyses on abuse 0/1 (CC and CO)
(r = 0.54) and lowest between the dimensional CO approach using CTQ
score and the GxE interaction approach using abuse 0/1 (r = 0.33). The
overlap between SNPs with a notable p-value <0.001 is given in the
Venn diagram (supplemental Figure S3). Although in theory all
approaches were applied to measure GxE interaction for CT in
MDD, the overlap between all three analyses with p < 0.001 was only
one SNP (rs10504767) on chromosome eight with no known gene
nearby.
3.3.2 | Lookup of candidate genes
We performed a gene-based test using VEGAS2 (Mishra &Macgregor,
2015) on the genome-wide summary statistics of the three main
TABLE 2 List of top independent signals from the three meta-analyses (case-control GxE, case-only with abuse 0/1 and case-only with CTQ-
score) assuming an additive SNP effect (p < E-5); * log(OR); **beta
RSID MAF p-value Effect Genes nearby Alleles CHR I2 Sirection
Gene information from NCBI
resource
Case-only analysis (dichotomous childhood abuse 0/1)*
rs17578476 0.27 3.3E-6 −0.368 LRRIQ3 AC chr1 0.0 − − − − A SNP at the LRRIQ3 Locus has
been associated
with SCZ
rs6553019 0.40 5.1E-6 0.321 FAT1 AG chr4 46 + + + + Probable function as an adhesion
molecule or signaling receptor,




rs10846719 0.49 5.6E-6 0.335 SCARB1, NCOR2 TC chr12 0.0 + + + ? plasma membrane receptor for
high density lipoprotein
cholesterol (HDL)
rs10504765 0.39 9.5E-6 −0.547 – AG chr8 0.0 − − ? −
Case-only analysis (dimensional CTQ score)**
rs3214187 0.13 7.4E-7 −3.443 NPY D_I3 chr7 48 − − − − Widely expressed in the central
nervous system and influences
many physiological processes,
including cortical excitability,
stress response, food intake,
circadian rhythms, and
cardiovascular function
rs199719135 0.09 1.5E-6 6.044 SH3BP4 D_I11 chr2 62 + + ? + Involved in cargo-specific control
of clathrin-mediated
endocytosis
rs75184661 0.06 4.1E-6 5.479 CACNA1C (intronic) TC chr12 0.0 ? + + + Mediate the influx of calcium ions
into the cell upon membrane
polarization
rs6822352 0.34 6.8E-6 2.291 KDR AG chr4 16 + + + ? VEGF receptor
rs6997589 0.26 7.7E-6 -3.575 SH2D4A (intronic) AG chr8 0.0 − − ? −
rs200510841 0.23 9.9E-6 3.787 SEMA6D D_I2 chr15 0.0 + + ? + Mediates transport to and from
the nucleus
GxE analysis (dichotomous childhood abuse 0/1)*
rs7128637 0.26 4.4E-6 −0.880 ARHGAP20 CG chr11 0.0 − − ? −
rs10772578 0.06 6.0E-6 1.268 CREBL2 TC chr12 45 + + + + Suggestions that CREBL2 encodes
a protein with DNA binding
capabilities and has tumor-
suppressor properties
rs10808504 0.44 7.9E-6 0.755 ENPP2 TC chr8 0.0 + + ? + Regulating myelin formation
I2 as measurement of heterogeneity between studies. Direction reporting the direction of effects in SHIP-0, TREND, NESDA, Radiant-UK.
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analyses assuming additive SNP-effects. The gene definitionwas set to
±10 kb and all SNPs per gene were used for analysis. No gene was
significant after correction for multiple testing and the top results
contained no gene previously associated with a psychiatric phenotype
(supplemental Table S5). Also our list of candidate genes revealed not
even a nominally significant (p < 0.05) hit in the VEGAS2 results
(supplemental Tables S6).
4 | DISCUSSION
This is the first genome-wide GxE interaction GWAS for depression
andCT in subjects of European ancestry. The aims of this studywere to
validate candidate SNPs and genes for GxE in MDD while applying
different model assumptions to acknowledge the variety of GxE
models in previous candidate gene studies. Our methods included
standard case-control GxE analysis with a multiplicative interaction
term as well as case-only analyses with two different parametrizations
of CT (dichotomous childhood abuse 0/1 and a continuous CT score)
assuming an additive SNP-effect.
Two published GxE studies on depressive symptoms reported
genome-wide significant SNPs inAfricanAmericanwomen (rs4652467)
(Dunn et al., 2016) and in a Japanese population (rs1051057) (Otowa
et al., 2016).Wewere not able to replicate these findings as rs4652467
only has a MAF < 0.001 in populations of European ancestry and was
therefore excluded from our analyses. The association between
rs1051057 and MDD in this sample was non-significant, even at a
nominal level. One explanation for our failure to replicate this finding
could be due to the different phenotype definition, as we used lifetime
MDD and not current depressive symptoms. As expected, due to the
limited number of subjects, we were underpowered to identify robust
genome-widesignificant interactioneffects in3944 individuals.Noneof
the genome-wide approaches suggested an inflation of the p-values in
the QQ-plots (supplemental Figure S2).
Overall, the candidate variants could not sufficiently be supported
by our analyses; only 9% of the SNPs revealed a nominally significant
effect in at least one of the three main approaches. Also the
introduction of dominant and recessive SNP models led to no
association with p < 0.0003. Subsequent gene-based analyses on the
summary statistics using VEGAS2 allowed for no biologically
meaningful interpretation. These findings are also consistent with
recent large-scale efforts to validate candidate genes, especially the 5-
HTTLPR variant (Culverhouse et al., 2017). With such limited
validation of candidate variants it seems questionable if the current
approaches of candidate gene studies are the right tool to gain insights
into the biology of gene-environment interactions inMDD.Our results
suggest that published studies on candidate variants in GxE for MDD
are in part likely subject to publication bias.
4.0.3 | Methodological limitations and challenges
GxE studies face even larger methodological challenges than genetic
association studies looking for main effects of SNPs.
1. Power: Our main limitation was the lack of power due to the limited
sample size in our analysis which only allows for the robust
identification of huge genetic effects which are not expected when
analyzing common variants. We tried to circumvent this limitation
by focusing on previously reported candidate variants.
2. Assumptions behind GxE models: The methodological approaches
that have been performed are based on different assumptions. In
case-only analysis, independence between the genetic signal and
the environmental factor is required. This might be a problem as
studies suggest a significant heritability of childhood adversity
through inherited ways of behavior. Nevertheless, as previously
shown for the MDD PGC wave2 data, SNP heritability for CT was
estimated to be not significantly different from 0.00 in GRM based
analyses (Peyrot et al., 2017). Because of limited sample size,
estimating the proportion of variance attributable to the interaction
betweenCT and genome-wide genetic effectswas not possible. But
we also found no evidence for a gene-environment correlation for
the top hits of our meta-analyses.
3. Heterogeneity across samples: The samples used in these analyses
were taken from different settings, general population and clinical
patients. Although this might have biased the results, all subjects
were of European ancestry, all subjectswere screened forMDDwith
the same instrument, all controls were also screened for absence of
MDD and CT was assessed using the same instrument (CTQ).
4. Childhood trauma measurement: As with many other measures for
CT, the CTQ is a retrospective self-report measure and thus reports
are likely to be influenced by recall bias and particularly depressive
state. One solution would be to control for mood at the time of
reporting in the analyses (Fisher et al., 2013). But other groups have
found that depressive symptoms do not result in exaggeration of
retrospectively recalled stressful events (Brewin, Andrews, &
Gotlib, 1993; Fisher et al., 2011) and thus the use of retrospective
self-reports is likely to have had only a minimal impact on these
results. Nevertheless, this could be a source of bias leading to false
positive results in our analyses.
5. GxE models: Although a number of different model assumptions
were tested in this study, there are other models that need further
investigation like the distinction between additive and multiplica-
tive interaction models which is circumvented in the case-only
approach as this method is assuming a multiplicative interaction.
Also environmental factors different from CT such as social status
or BMI could exhibit a GxE interaction as these are also risk factors
for depression (Mansur, Brietzke, & McIntyre, 2015; Schlossberg,
Massler, & Zalsman, 2010).
6. Lack of replication samples: We had no independent replication
samplesbutweuseddifferentmodels to assess the robustnessof the
results. Unfortunately, no consistency between models was found.
7. Coverage of genetic variants: A GWAS approach does not cover all
possible genetic variants that could contribute to depression, for
example, insertions, deletions or rare genetic variants. One of the
most prominent examples is the serotonin-transporter polymor-
phism (Caspi et al., 2003).
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Nevertheless, our analyses may provide some insights into GxE
analyses and the genetic underpinning of gene-environment inter-
actions in MDD as some of the top signals in the three main analyses
involved genes previously implicated in psychiatric phenotypes (Table
2) like ENPP2 (Aston, Jiang, & Sokolov, 2007) the LRRIQ3 Locus
identified in the latest GWAS for schizophrenia (Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014),
FAT1 (Abou Jamra et al., 2008; Light et al., 2005),NPY (Nakhate, Yedke,
Bharne, Subhedar, Kokare, 2016; Soleimani et al., 2014) and
CACNA1C, a candidate gene in depression that also shows pleiotropic
effects on other major psychiatric disorders (Cross-Disorder Group of
the PGC, 2013; Rao et al., 2016). Although some of these genes are
well known in psychiatric research, the significant SNPs from the
analyses showed no overlap with previously identified candidate SNPs
of these genes.
Finally, we can say that with the current sample size we were not
able to detect a robust genome-wide significant interaction with
childhood trauma and depression and most of the candidate variants
and genes could not be supported when utilizing different methodo-
logical approaches. An important point of this analysis is the lack of
replication, even if only nominal p-values are considered. Moreover,
the analyses showed a lack of stability of findings in the different
methodological approaches.
It will be necessary to collect more data on CT in MDD samples to
validate our top hits and achieve a higher power to detect robust
genome-wide significant findings. Also it might be prudent to at least
partially question some of the former candidate SNP results for MDD
as these could be attributed to publication bias and inconsistent
models. One approach could be to harmonize the different CT
measures throughout all of the PGC cohorts and perform the analyses
with amuch larger sample size.We also recommend reconsideration of
the differentmodels currently performed inGxE analyses forMDDand
to perform consistent analyses in samples large enough to identify
robust GxE interaction signals. Our next steps will be to perform the
GxE analyses on single sub-dimensions of abuse where we have more
data within the PGC as well as performing the analysis under the
assumption of an additive interaction effect.
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